Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality

Table 5 Predictors of USRDS-documented end-stage renal disease (ESRD) after liver transplantation

	Adjusted ^b Relative Hazard of ESRD
Characteristic	HR	[95% C.I.]	p-value
Diabetes
No	1.0	Reference
Yes	2.6	[1.3, 5.2]	0.005
MELD score category
< 20	1.0	Reference
20–29	2.2	[1.0, 4.7]	0.04
≥ 30	2.6	[1.0, 6.4]	0.04
	p-trend = 0.02
MELD Era
Pre-MELD era (<2/02)	1.0	Reference
MELD era (≥2/02)	2.0	[0.8, 5.1]	0.13
eGFR category at OLT
≥ 90	1.0	Reference
60–89	2.6	[0.9, 7.0]	0.07
30–59	2.6	[1.0, 7.0]	0.06
< 30	4.9	[1.6, 14.6]	0.005
	p-trend = 0.006
Hepatorenal syndrome
No	1.0	Reference
Yes	3.8	[1.4, 10.3]	0.01
Hepatitis C virus infection
No	1.0	Reference
Yes	1.9	[1.0, 3.9]	0.065
Calcineurin inhibitor use^b
Tacrolimus	1.0	Reference
Cyclosporine	1.0	[0.4, 3.1]	0.94
Type not known	0.7	[0.3, 1.6]	0.40

^a All models include age, gender, diabetes, and time-dependent eGFR category. Note: ESRD was not significantly associated in the adjusted models with age, sex, race, cause of liver failure, hypertension, hepatocellular carcinoma, mycophenolate mofetil use, or steroid use
^b The “None” category for CNI use had too few observations for inclusion in the model

ISSN: 1471-2369